Undisclosed Cell Therapy Programs
Challenging liquid and solid tumors
PreclinicalResearch & Development
Key Facts
Indication
Challenging liquid and solid tumors
Phase
Preclinical
Status
Research & Development
Company
About Senti Biosciences
Senti Bio is developing next-generation cell and gene therapies by programming cells with synthetic biology-based Gene Circuits, designed to outsmart complex diseases with enhanced logic and control. The company has advanced its lead wholly-owned program, SENTI-202, into clinical trials for AML and maintains a broader preclinical pipeline targeting both liquid and solid tumors. Led by synthetic biology pioneers and experienced biotech executives, Senti aims to overcome limitations of current cell therapies by creating more intelligent, targeted medicines.
View full company profile